Determining Which of Several Simultaneously Administered Vaccines Increase Risk of an Adverse Event.


Journal

Drug safety
ISSN: 1179-1942
Titre abrégé: Drug Saf
Pays: New Zealand
ID NLM: 9002928

Informations de publication

Date de publication:
10 2020
Historique:
pubmed: 3 7 2020
medline: 24 8 2021
entrez: 3 7 2020
Statut: ppublish

Résumé

Childhood immunization schedules often involve multiple vaccinations per visit. When increased risk of an adverse event is observed after simultaneous (same-day) vaccinations, it can be difficult to ascertain which triggered the adverse event. This methods paper discusses a systematic process to determine which of the simultaneously administered vaccine(s) are most likely to have caused an observed increase in risk of an adverse event. We use an example from the literature where excess risk of seizure was observed 1 day after vaccination, but same-day vaccination patterns made it difficult to discern which vaccine(s) may trigger the adverse event. We illustrate the systematic identification process using a simulation that retained the observed pattern of simultaneous vaccination in an empirical cohort of vaccinated children. We simulated "true" effects for diphtheria-tetanus-acellular pertussis (DTaP) and pneumococcal conjugate (PCV) on risk of seizure the day after vaccination. We varied the independent and interactive effects of vaccines (on the multiplicative scale). After applying the process to simulated data, we evaluated risk of seizure 1 day after vaccination in the empirical cohort. In all simulations, we were able to determine which vaccines contributed to excess risk. In the empirical data, we narrowed the association with seizure from all vaccines in the schedule to three likely candidates, DTaP, PCV, and/or Haemophilus influenzae type B (HiB) (p < 0.01, attributable risk when all three were administered together: five per 100,000). Disentangling their associations with seizure would require a larger sample or more variation in the combinations administered. When none of these three were administered, no excess risk was observed. The process outlined could provide valuable information on the magnitude of potential risk from individual and simultaneousvaccinations. Associations should be further investigated with independent data as well as biologically based, statistically independent hypotheses.

Identifiants

pubmed: 32613596
doi: 10.1007/s40264-020-00967-8
pii: 10.1007/s40264-020-00967-8
pmc: PMC7501163
mid: NIHMS1608870
doi:

Substances chimiques

Diphtheria-Tetanus-acellular Pertussis Vaccines 0
Haemophilus Vaccines 0
Haemophilus influenzae type b polysaccharide vaccine 0
Pneumococcal Vaccines 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1057-1065

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI107721
Pays : United States

Références

Vaccine. 2014 Sep 22;32(42):5390-8
pubmed: 25108215
Vaccine. 2009 Aug 27;27(39):5307-12
pubmed: 19616500
Pediatr Infect Dis J. 2014 Jan;33(1):73-80
pubmed: 24346596
Vaccine. 2006 May 15;24(20):4321-7
pubmed: 16581162
Pediatrics. 2016 Jul;138(1):
pubmed: 27273711
Vaccine. 2016 Jun 8;34(27):3030-3036
pubmed: 27160040
Pediatr Infect Dis J. 2004 Mar;23(3):240-5
pubmed: 15014300
JAMA. 2012 Feb 22;307(8):823-31
pubmed: 22357833
Hum Vaccin Immunother. 2013 Aug;9(8):1691-7
pubmed: 23744509
Pharmacoepidemiol Drug Saf. 2010 May;19(5):529-32
pubmed: 20309840
Int J Epidemiol. 1981 Dec;10(4):383-7
pubmed: 7327838
Am J Epidemiol. 1980 Oct;112(4):467-70
pubmed: 7424895
Pediatrics. 2015 Oct;136(4):e848-55
pubmed: 26371192

Auteurs

Shirley V Wang (SV)

Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA, 02120, USA. swang1@bwh.harvard.edu.

Kristina Stefanini (K)

Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA, 02120, USA.

Edwin Lewis (E)

Kaiser Permanente Vaccine Study Center, Oakland, CA, USA.

Sophia R Newcomer (SR)

Institute for Health Research, Kaiser Permanente Colorado, Denver, CO, USA.

Bruce Fireman (B)

Kaiser Permanente Division of Research, Oakland, CA, USA.

Matthew F Daley (MF)

Institute for Health Research, Kaiser Permanente Colorado, Denver, CO, USA.
Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA.

Jason M Glanz (JM)

Institute for Health Research, Kaiser Permanente Colorado, Denver, CO, USA.
Colorado School of Public Health, University of Colorado Denver, Aurora, CO, USA.

Jonathan Duffy (J)

Immunization Safety Office, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Eric Weintraub (E)

Immunization Safety Office, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Martin Kulldorff (M)

Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 1620 Tremont Street, Suite 3030, Boston, MA, 02120, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH